Vikas Dandekar
Editor, Pharma and Life Science at ET Prime
Journalist - Indian pharma & healthcare. Views own [email protected]
Articles
-
2 months ago |
economictimes.indiatimes.com | Teena Thacker |Vikas Dandekar
The Drug Controller General of India has ordered a ban on the production of tapentadol and carisoprodol, the two drugs earlier found to be illegally exported to African nations, such as Ghana and Nigeria, and blamed for causing a serious public health crisis of opioid addiction.The issue came under the spotlight as part of a recent BBC investigation that exposed a racket, where an Indian producer was exporting the unlicensed addictive combination.Tapentadol is a strong opioid and is used to...
-
Jan 6, 2025 |
economictimes.indiatimes.com | Vikas Dandekar
MUMBAI: Intas Pharmaceuticals ' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon Pfizer , Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences .
-
Dec 19, 2024 |
insights.citeline.com | Jessica Merrill |Vikas Dandekar
Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth FocusIn a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.
-
Nov 8, 2024 |
flipboard.com | Vikas Dandekar
19 hours agoIt's not all related to menopause, experts discovered. Talk about a birthday gift I wish I could mark “return to sender.” Just two weeks shy of turning 42, this ominous headline crossed my Slack: “Human aging accelerates dramatically at age 44 and 60.” Now, I’m no great mathematician, but even I can …
-
Oct 13, 2024 |
flipboard.com | Vikas Dandekar
Only 12% clinicians in India use AI in decision-making, it can shoot to 79% in 2-3 years: Jan Herzhoff, President (health markets), ElsevierDr Jan Herzhoff, President (health markets) at the global information and analytics group Elsevier was India recently to participate in a global …
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 13K
- Tweets
- 30K
- DMs Open
- Yes
On, off, on, off !! Tariff Live Updates: Trump Backs Down on Reciprocal Tariffs for 90 Days https://t.co/xHJHIgb1ln
RT @EconomicTimes: #ETMorningBriefPodcast: Corner Office Conversation with #EliLilly's Global CEO David Ricks | Listen in with @VikasReport…
On his recent visit to India, Eli Lilly's Global CEO David Ricks spoke on a wide band of issues on our @EconomicTimes The Morning Brief #podcast @Teensthack ... thanks @AnirbanET and his cracker team for this very important episode. https://t.co/GDliEQI13w